抗PM-Scl抗体相关系统性硬化症合并包涵体肌炎:两例报告及文献复习
本文报告两例抗PM-Scl抗体相关系统性硬化症女性患者出现进行性近端肌病,肌活检证实为包涵体肌炎(IBM),对糖皮质激素联合或不联合口服免疫抑制剂治疗无效。加用每月静脉注射免疫球蛋白(IVIG)后,一例肌病暂时稳定但残留严重肌无力,另一例仍缓慢进展。作者结合既往两例类似病例比较,提出自身免疫性肌肉病可能触发肌变性的假说。
要点
- 抗PM-Scl抗体相关系统性硬化症患者出现难治性近端肌无力时,需考虑合并包涵体肌炎的可能。
- 两例患者肌活检均显示包涵体肌炎,对糖皮质激素及口服免疫抑制剂反应不佳。
- 每月IVIG(2 g/Kg)治疗后一例暂时稳定、一例仍缓慢进展,提示该关联极罕见且治疗困难。
核心结论
- IBM与抗PM-Scl抗体相关硬化性肌病的关联极罕见,为IBM可能的发病机制提供了新线索。
- 该关联强化了自身免疫性肌肉病可能触发肌变性的假说。
- 早期积极免疫抑制治疗能否阻止进展为治疗难治性IBM,应是未来研究的方向。
研究设计与样本
- 病例报告:两例抗PM-Scl抗体相关系统性硬化症女性患者,因进行性近端肌病行股四头肌活检证实包涵体肌炎。
- 文献复习:将本两例与既往报告的两例类似病例进行比较,并探讨该关联的可能病理机制。
主要发现
- 两例患者均有严重肌无力,对糖皮质激素联合或不联合其他口服免疫抑制剂治疗无效。
- 两例股四头肌活检均提示包涵体肌炎(IBM)。
- 一例在每四周IVIG(2 g/Kg)输注后肌病似乎暂时稳定,但严重残留肌无力持续存在。
- 另一例在接受每四周IVIG、每周口服甲氨蝶呤及每6个月利妥昔单抗输注的情况下,肌病仍继续缓慢进展。
关键数值与推荐
- IVIG用法:每四周输注2 g/Kg。
- 一例联合每周口服甲氨蝶呤及每6个月利妥昔单抗输注。
临床怎么用
- 对抗PM-Scl抗体相关系统性硬化症患者出现难治性近端肌无力时,应行肌肉活检以排查包涵体肌炎。
- 确诊合并IBM后,可考虑加用每月IVIG(2 g/Kg),但需告知疗效可能有限且肌病仍可进展。
局限性
- 仅为两例病例报告及文献复习,样本量小,无法确立因果关系或疗效结论。
- IVIG等治疗后的肌病变化为临床观察描述,缺乏对照或客观疗效评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe two cases of anti-PM-Scl antibody-associated systemic sclerosis with evidence of inclusion body myositis on muscle biopsy. METHODS: Two female patients with anti-PM-Scl antibody-associated systemic sclerosis developed progressive proximal myopathy. Both patients had profound muscle weakness that was refractory to treatment with glucocorticoids with or without other oral immunosuppressive agents. Quadriceps muscle biopsy in both cases indicated inclusion body myositis (IBM). Monthly intravenous immunoglobulin (IVIG) infusions were added to the treatment regimen. RESULTS: One patient's myopathy appears to have temporarily stabilized with IVIG infusions (2 g/Kg) every four weeks, though severe residual muscle weakness has persisted. The other patient's myopathy continues to progress slowly, despite being on 4-weekly IVIG infusions, along with weekly oral methotrexate and 6-monthly rituximab infusions. In this report, we compare these two patients with two similar cases that were previously reported and hypothesize a possible pathomechanism of this association. CONCLUSION: This extremely rare association of IBM and anti-PM-Scl antibody-associated scleromyositis sheds new light on the possible pathogenesis of IBM. It strengthens the hypothesis that autoimmune muscle disease can potentially trigger myodegeneration. Whether early intervention with aggressive immunosuppressive therapy can prevent progression to treatment-refractory IBM, should be a subject of future research.
引用
- Chatterjee S, Prayson RA. Concurrent anti-PM-Scl antibody-associated systemic sclerosis and inclusion body myositis - report of two cases and review of the literature. Semin Arthritis Rheum. 2019. PMID: 31806155. doi:10.1016/j.semarthrit.2019.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。